Hdc-2A-CreERT2

Nomenclature

C57BL/6Smoc-Hdcem(2A-CreERT2)Smoc

Cat. NO.

NM-KI-220044

Strain State

Sperm cryopreservation

Export PDF

Gene Summary

Gene Symbol
Hdc

Synonyms

Hdc-a; Hdc-c; Hdc-e; Hdc-s; AW108189

NCBI ID

15186

MGI ID

96062

Ensembl ID

ENSMUSG00000027360

Pubmed

Hdc

Human Ortholog

HDC

Model Description

2A-CreERT2 expression cassette was knocked into the Hdc gene stop codon site.

Validation Data

image.png

Fig1. CreERT2 mediated recombination in brain of HdcCreERT2/+; Rosa26tdTomato/+ mouse. 

image.png

Fig2. Detection of tdTomato(red) in various tissues of HdcCreERT2/+; Rosa26tdTomato/+ mouse. 

The tissues that express tdTomato include: brain, spinal cord, lungs, liver, stomach, adrenal glands, kidneys, spleen, reproductive organs, thymus, and pituitary gland. Tissues with minimal tdTomato expression include: small intestine and skin. 

Tissues that do not express tdTomato: heart, eyes, salivary glands, brown adipose tissue, pancreas, large intestine, and muscle. 

In the control group, tdTomato shows very minimal leaky expression in the brain, stomach, adrenal glands, kidneys, spleen, and thymus. (8-weeks old, male) (For more detailed information please contact our technical advisor.) 

Publications 1piece

1. An H2R-dependent medial septum histaminergic circuit mediates feeding behavior
Published year：2022-03-25 References：Current Biology

展开

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more